A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP
Status:
Withdrawn
Trial end date:
2020-08-05
Target enrollment:
Participant gender:
Summary
This is a Phase 2 randomized, dose-blind, multicenter study designed to evaluate the safety,
tolerability, efficacy, Pharmacokinetics (PK), and Pharmacodynamics (PD) of treatment with
KZR-616 in patients with active Autoimmune Hemolytic Anemia or Immune Thrombocytopenia.